<DOC>
	<DOC>NCT00449722</DOC>
	<brief_summary>To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis</brief_summary>
	<brief_title>OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Inclusion Criteria (main): Active ulcerative colitis except proctitis, i.e. inflammation minimal 15cm ab ano, confirmed by endoscopy and histology Established or new diagnosis Disease activity at baseline: Clinical Activity Index (CAI) &gt;4 and Endoscopic Index (EI) &gt;= 4 Exclusion Criteria (main): Crohn's disease Toxic megacolon Present or past colorectal cancer Symptomatic gastrointestinal disease Serious secondary disease(s) Baseline stool positive for germs causing bowel disease Immunosuppressants within 3 months and/or corticosteroids within 1 month prior to baseline Current relapse occurred under maintenance treatment with &gt;2g/day mesalazine Serum creatinine &gt;= 1.2x upper limit of normal (ULN) and creatinine clearance &lt; 60 ml/min per 1.73 m2 Serum transaminase (ALT and/or AST), and/or alkaline phosphatase &gt;= 2x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>